Silvio Veronese

发表

The TPM3‐NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition

Andrea Lombardi Borgia, Antonella Isacchi, Roberta Bosotti, 2014, Molecular oncology.

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets

Marco Beccuti, Francesca Cordero, Claudio Isella, 2015, Nature Communications.

Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer

Enzo Medico, Roberta Schiavo, F. Nicolantonio, 2012, Nature.

Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

Beatriz Bellosillo, Enzo Medico, Giuseppe Rospo, 2015, Nature Medicine.

Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations.

Lefteris Angelis, Véronique Giudicelli, Marco Montillo, 2015, Blood.

Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer.

Andrea Bertotti, Simona Corso, Maria Apicella, 2013, Cancer discovery.

Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study.

Lefteris Angelis, Véronique Giudicelli, Marco Montillo, 2014, The Lancet. Haematology.

PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.

Francesca Molinari, Michele Nichelatti, L. Mazzucchelli, 2009, Cancer research.

Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.

Silvia Benvenuti, M. Moroni, A. Bardelli, 2005, The Lancet. Oncology.

Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies.

Silvia Benvenuti, M. Moroni, A. Bardelli, 2007, Cancer research.